MENU
Showcases Stock ranks Forex

Fate Therapeutics (FATE)
34.14  0.72 (2.15%) 08-08 16:00
Open: 33.99 Pre. Close: 33.42
High: 37.13 Low: 33.7101
Volume: 2,013,455 Market Cap: 3,312M
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 37.176 - 37.314 37.314 - 37.424
Low: 33.364 - 33.525 33.525 - 33.655
Close: 33.898 - 34.147 34.147 - 34.347
Stock Technical Analysis
Overall:     
Target: Six months: 43.37
One year: 50.65
Support: Support1: 30.86
Support2: 26.99
Resistance: Resistance1: 37.13
Resistance2: 43.37
Pivot: 32.07
Moving Averages: MA(5): 32.71
MA(20): 31.80
MA(100): 29.41
MA(250): 43.73
MACD: MACD(12,26): 1.43
Signal(12,26,9): 1.46
%K %D: %K(14,3): 55.95
%D(3): 53.93
RSI: RSI(14): 63.35
52-Week: High: 97.43
Low: 17.1
Change(%): -61.0
Average Vol(K): 3-Month: 1604
10-Days: 1233
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ FATE ] has closed below upper band by 7.4%. Bollinger Bands are 46.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Mon, 08 Aug 2022
Global Natural Killer (NK) Cell Therapeutics Markets, 2022-2032 - Increasing Funding and Investment & Rising Number of Partnerships and Collaborations - Yahoo Finance

Wed, 03 Aug 2022
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress - GlobeNewswire

Wed, 03 Aug 2022
Roche digs into off-the-shelf cell therapy with Poseida deal - BioPharma Dive

Wed, 03 Aug 2022
XBI, BEAM, FATE, NTLA: ETF Outflow Alert - Nasdaq

Mon, 25 Jul 2022
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results - GlobeNewswire

Thu, 21 Jul 2022
Critical Comparison: Ambrx Biopharma (NYSE:AMAM) & Fate Therapeutics (NASDAQ:FATE) - Defense World

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 96.63
Shares Float (M) 82.73
% Held by Insiders 1.46
% Held by Institutions 108.42
Shares Short (K) 21220
Shares Short Prior Month (K) 20600
Stock Financials
EPS -2.440
Book Value (p.s.) 5.990
Profit Margin
Operating Margin -412.53
Return on Assets (ttm) -19.3
Return on Equity (ttm) -38.1
Qtrly Rev. Growth 38.3
Gross Profit (p.s.) 0.578
Sales Per Share 0.706
EBITDA (p.s.) -2.816
Qtrly Earnings Growth
Operating Cash Flow (M) -221.44
Levered Free Cash Flow (M) -189.70
Stock Valuation
PE Ratio -13.99
PEG Ratio 0.28
Price to Book value 5.70
Price to Sales 48.33
Price to Cash Flow -14.90
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android